Articles On Patrys (ASX:PAB)

ShareCafeGlobal recession fears weigh in: ASX down 1.6% at noon by Lauren Hayes   US stocks closed the previous week lower after a University of Michigan survey showed inflation expectations were increasing. This rattled markets as equities...

ShareCafeStocks of the Hour: DRE, PAB, STK                    Dreadnought Resources (ASX:DRE) announced today that REE mineralised carbonatite intrusions have been confirmed at the C3 and C4 carbonatites. The company has intersected t...

Patrys crosses blood brain barrier in health animals Cynata receives Notice of Acceptance from IP Australia Telix announces collaboration with GE Healthcare Patrys (ASX:PAB) surged 15% this morning after announcing that its full-sized deo...

Therapeutic antibody development company Patrys (ASX:PAB) has announced new preclinical data for its full-sized IgG antibody, PAT-DX3.

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX is set to open much lower on Monday Wall Street plunged on Friday as earnings season starts RBA meeting minutes to be released this week Local shares are set to reverse Friday’s gains and dive lower today. At 8am AEST, the ASX 200...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Oncology company Patrys (PAB) completes specification tests of drug substance from its lead PAT-DX1 product, produced in a recently-completed engineering run The good manufacturing process (GMP) material produced passed all specification r...

Highlights: The ASX 200 benchmark index closed up today (26 August), gaining 0.79% to end the day at 7,104.10 points. Over the last five days, the index is virtually unchanged, but is down 4.57% for the last year to date. Telecom Serv...

The Victorian government awards Patrys (PAB) a $100,000 Victorian Medical Research Acceleration Fund (VMRAF) grant to support research for metastatic breast cancer The grant will go to the Olivia Newton-John Cancer Research Institute (ONJC...

Patrys gets research grant to progress lead drug Next Science gets Canada license   Bad news for IDT Australia Cancer fighter Patrys (ASX: PAB) has received a new $100k research grant to progress lead drug deoxymabs in treating Metastatic...

Therapeutic antibody development company Patrys (ASX:PAB) has announced new pre-clinical data for its lead asset, PAT-DX1, from a study conducted by Professor Terrence Johns of the Telethon Kids Cancer Centre.

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Patrys (ASX:PAB) has announced that its contract development manufacturing organisation has successfully completed a second engineering run that used an updated purification process to produce large-scale quantities of clinical-grad...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Patrys’ (PAB) Contract Development Manufacturing Organisation (CDMO) has completed the second engineering run for its cancer antibody candidate, PAT-DX1 The engineering run used an updated purification process to produce large-scale quant...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Emerging Companies (XEC) index tumbles 2.8%   Benchmark ASX200 down 7% over five sessions Square Inc is leaking   Small caps have been hit hard for the second consecutive day – down 2.8% and some 11% over the last five sessions. The ben...

Patrys (PAB) sees a range of PAT-DX1 studies published in peer-reviewed journal ImmunoHorizons supporting its use in treating certain cancers and inflammatory diseases Recent studies have shown neutrophil extracellular traps (NETs) play a...

Patrys (PAB) receives $250,000 in funding to support its research on treatments for brain cancer The Cure Brain Cancer Foundation allocated the funds to Patrys’ collaborator, Telethon Kids Institute The money will be used to identify poten...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Therapeutic antibody development company Patrys (ASX:PAB) has identified and selected an optimised stable cell line for the production of its full-sized IgG deoxymab, PAT-DX3.

Therapeutic antibody development company Patrys (PAB) identifies and selects an optimised stable cell line for production of its PAT-DX3 antibody The company says establishing the stable cell line for the production of PAT-DX3 has come ahe...

“With this key reagent now identified and in hand, we can rapidly move into developing a commercial-scale production process to support both the clinical and partnering opportunities we have for PAT-DX3,” says CEO & MD.

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

In a newsletter on Tuesday, CEO and managing director Dr James Campbell outlined the growing upside in the ADC space — and how Patrys is poised to capitalise on momentum.

The S&P/ASX200 climbed into the close on Tuesday. Most of the 35 or so point gain (0.5%)  comes off the back of some good, steady central banking, delivered – nay, telegraphed – at 2.30pm when the Reserve Bank (RBA) left the cash rate a...

When markets get the jitters, smaller companies are often in the firing line and ASX microcaps have copped the brunt of the impact from last week’s global stock selloff. The composite microcap Emerging Companies index slumped by more than 3...

The ASX 200 Health Index (XHJ) is falling by 0.3% at the time of writing, compared to the broader index which is down by 0.37%. Visioneering Technologies (ASX:VTI) has enrolled the first patient in its landmark international clinical trial...

The company's wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has also received a $1,188,581 R&D Tax Incentive Refund for the 2020/2021 financial year.

Patrys (PAB) completes the first engineering run of its cancer antibody candidate, PAT-DX1, resulting in a lower drug product recoveries than expected The product yield from the fermentation process was consistent with the small scale pilo...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The ‘Covid-induced trial, interrupted syndrome’ is no more apparent than within the walls of Imagion’s (ASX:IBX) San Diego headquarters, where the company is spearheading a new form of diagnostic imaging based on pin-pointed magnetic target...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

“Having two assets on the path to the clinic is a very exciting place to be, and makes Patrys a much more robust investment opportunity. I personally can’t wait to see what we learn and I encourage you to stay tuned for our updates," says C...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

He’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radiopharm Theranostics (ASX:RAD) to his boardroom rota after the nuclear medicine play listed on the ASX on Thursday – albeit limply. The count...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

“Based on the promising data we have seen for PAT-DX3 since we announced it 12 months ago, we believe there are a range of very attractive potential applications for this deoxymab that will significantly expand opportunities for internal de...

The ASX 200 Health Index (XHJ) is up by 1.30% at the time of writing, compared to the broader index which is higher by 0.5%. The US FDA has accepted the New Drug Application (NDA) for Maxigesic IV, AFT Pharma’s (ASX:AFP) intravenous form of...

Patrys (PAB) will be undertaking a $7.8 million capital raising, consisting of a placement and a fully-underwritten rights issue The placement will issue more than 71.4 million shares to institutional investor Territory Funds Management to...

After a positive Monday to Thursday, the ASX wiped out gains made across the week, losing more than 1% today The ASX followed a plunge on Wall Street with the ASX 200 closing at 7,324, which was 1.44% lower than yesterday’s close. While Wal...

Local stocks lost ground on Thursday, with minor falls at the big end of town and a slightly steeper drop of ~0.8% for the microcap Emerging Markets Index. The ASX opened with a weak lead from Wall Street, after a fortnight of steady gains...